|MDACC Study No:||2013-0209 (clinicaltrials.gov NCT No: NCT01849874)|
|Title:||The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum|
|Principal Investigator:||Robert Coleman|
|Treatment Agent:||Liposomal Doxorubicin; MEK162; Paclitaxel; Topotecan |
|Study Description:||The goal of the main part of this clinical research study is to learn if MEK162 |
can help to control cancers of the ovary, fallopian tube, or primary
peritoneum. In this study, MEK162 will be compared to 3 other chemotherapy
drugs. The safety of MEK162 and the other drugs will also be studied.
The goal of the screening part of this study is to learn if you are eligible to
take part in the main study.